TY - JOUR
T1 - Treatment of the antiphospholipid antibody syndrome
T2 - progress in the last five years?
AU - Petri, M.
PY - 2000/6
Y1 - 2000/6
N2 - The gold standard for treatment of the antiphospholipid antibody syndrome (APS) after thrombosis remains high-intensity warfarin, and, in pregnancy, heparin and aspirin. Exciting developments include the potential role of hydroxychloroquine as a prophylactic drug, stem cell transplantation, and B-cell tolerance. Animal models appear to be a fruitful "proving ground" of new therapies. The introduction of revised classification criteria for APS should aid in appropriate characterization of, and selection of, patients for clinical trials.
AB - The gold standard for treatment of the antiphospholipid antibody syndrome (APS) after thrombosis remains high-intensity warfarin, and, in pregnancy, heparin and aspirin. Exciting developments include the potential role of hydroxychloroquine as a prophylactic drug, stem cell transplantation, and B-cell tolerance. Animal models appear to be a fruitful "proving ground" of new therapies. The introduction of revised classification criteria for APS should aid in appropriate characterization of, and selection of, patients for clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=0034207976&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034207976&partnerID=8YFLogxK
U2 - 10.1007/s11926-000-0088-5
DO - 10.1007/s11926-000-0088-5
M3 - Review article
C2 - 11123068
AN - SCOPUS:0034207976
SN - 1523-3774
VL - 2
SP - 256
EP - 261
JO - Current rheumatology reports
JF - Current rheumatology reports
IS - 3
ER -